The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per month without leaving the platform.
News|Articles|June 3, 2026
Eli Lilly to Deny 340B Drug Pricing Due to Claims-Data Policy: Report
Author(s)Nicholas Jacobus
Eli Lilly moves to deny 340B discounts to hospitals refusing to submit claims data under its documentation policy, escalating a months-long standoff with the American Hospital Association and prompting calls for federal intervention.
Advertisement
Advertisement
Eli Lilly moved to cut off
Related to this article
As Medicare negotiation, PBM reform, and cash-pay channels converge, winning on auditable net value matters more than cutting list prices.
Dr. Jay Lalezari, CEO and CMO of CytoDyn, discusses how Leronlimab’s unique CCR5-blocking mechanism has carried it from HIV, to Covid-19, to a promising, one-of-a-kind proof of concept in colorectal cancer.
Dr. Jay Lalezari of CytoDyn explains why Leronlimab’s circulating tumor DNA results in colorectal cancer represent a unique, mechanism-specific proof of concept rather than a broader template.
PhRMA's Scott LaGanga discusses the expanding influence of state policymaking on drug pricing, PBM reform, and efforts to translate policy changes into lower out-of-pocket costs for patients.
FDA grants accelerated approval to INOVIO’s Voceryq for reducing surgery frequency in adults with recurrent respiratory papillomatosis.
Dr. Jay Lalezari, CytoDyn’s CEO and CMO, discusses his path from HIV clinician to drug developer.
ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics, as Egetis separately agrees to sell its priority review voucher for $190 million.
Advertisement
Advertisement